Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra fallout

This article was originally published in The Tan Sheet

Executive Summary

Incoming legal claims related to ephedra-containing products sold by Rexall Sundown and GNC "continue to reflect a stable trend," Dutch firm Numico maintains. Since the beginning of May, active cases filed against GNC and Rexall increased by 44, Numico says. The firm retained litigation risk when it divested the subsidiaries in 2003, and reported 137 liability suits had been filed as of March 1 (1"The Tan Sheet" March 8, 2004, p. 10). Numico continues to stress it has "adequate insurance in the form of an occurrence-based policy" to cover its ephedra risk...

You may also be interested in...



GNC Liability In Ephedra Lawsuits Is Limited, Numico Says

Rexall Sundown and GNC have been named in 137 product liability lawsuits involving ephedrine alkaloid-containing dietary supplements, former parent company Royal Numico disclosed in a year-end financials release March 4

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel